npj Breast Cancer, Published online: 07 November 2026; doi:10.1038/s41523-026-01075-z First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation
Po-Huang Chen, Hsin-Chung Lin, Ming-Shen Dai, Hsin-Yu Chen, Hong-Jie Jhou, Cho-Hao Lee. First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation. // npj Breast Cancer. – 2026. – DOI: 10.1038/s41523-026-01075-z. – URL: https://www.nature.com/articles/s41523-026-01075-z
Po-Huang Chen, Hsin-Chung Lin, Ming-Shen Dai, Hsin-Yu Chen, Hong-Jie Jhou, & Cho-Hao Lee (2026). First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation. npj Breast Cancer. https://doi.org/10.1038/s41523-026-01075-z
Po-Huang Chen, et al. “First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation.” npj Breast Cancer, 2026. doi:10.1038/s41523-026-01075-z.
@article{Chen2026,
title = {First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation},
author = {Chen, Po-Huang and Lin, Hsin-Chung and Dai, Ming-Shen and Chen, Hsin-Yu and Jhou, Hong-Jie and Lee, Cho-Hao},
journal = {npj Breast Cancer},
year = {2026},
doi = {10.1038/s41523-026-01075-z},
url = {https://www.nature.com/articles/s41523-026-01075-z}
}